|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||43.88 - 43.98|
|52 Week Range||35.52 - 44.21|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
Investors love exchange-traded funds. Critics can critique, but 2016's ETF inflows records were toppled with more than three months left in 2017. Underscoring the struggles faced by actively managed funds ...
Harvard Management Company CEO N.P. Narvekar in his State of HMC letter wrote: "Our performance is disappointing and not where it needs to be." Narvekar is making changes he thinks will produce better returns more efficiently over time. Narvekar explains: HMC’s investment professionals have historically focused their work within specific asset classes. Portfolio managers conducted research and analysis and executed investment decisions within their respective asset class independent of the rest of the portfolio, sometimes creating both gaps in the portfolio and unnecessary duplication.
AstraZeneca’s (AZN) stock value has fallen ~11.9% over the last 12 months. Wall Street analysts estimate that the stock has the potential to return ~16.6% over the next 12 months.
U.S. markets were destabilized in August after pushing toward record highs as a bout of political risks abroad and at home caused many traders to sell and lock in recent gains. Meanwhile, exchange traded ...
GlaxoSmithKline's Pharmaceuticals segment reported revenues of 4.36 billion pounds during 2Q17—12% growth compared to 2Q16.
Novartis missed the analysts’ estimate for 2Q17 revenues, reporting $12.24 billion and falling short of $12.27 billion, but surpassed the estimate for EPS.
Todd Rosenbluth is director of ETF and mutual fund research at CFRA. Did you catch Monday’s total solar eclipse? If so, your next opportunity isn’t expected until October 2023, according to NASA. Yet when the sun is shining brightly and unblocked, headlines tend not to be written and people don’t line up staring at the sky with cool glasses. This reminds us of the rarity of ETF trading on Aug. 24, 2015.
In 1H17, Fresenius Medical Care (FMS) reported revenues close to 9.0 billion euros, which represents 14% YoY growth. At the end of 2Q17, the company operated 3,690 dialysis clinics around the world.
Investors are loving international equity exchange-traded funds this year. That well-documented theme is confirmed by the fact that five of the top 10 asset-gathering ETFs on a year-to-date basis track ...
Only seven months into the year, and U.S.-listed ETFs have already attracted roughly $274 billion in net creations. That number is quickly reaching what currently stands as the industry’s all-time annual inflow record of $287.5 billion, which was notched last year. And we still have five months to go before the year is over.
In its earnings release on July 26, GlaxoSmithKline (GSK) reported 12% growth to ~7.3 billion pounds in its 2Q17 revenues. GSK surpassed analysts’ estimates for revenues and earnings per share.
Wall Street analysts estimate that GSK's top line will rise 11.4% to ~7.3 billion British pounds for 2Q17. Its EPS is expected come in at 0.26 pounds.
Novartis (NVS) released its 2Q17 earnings on July 18, 2017. It reported flat revenues at constant exchange rates compared to 2Q16.
Hear what Vanguard's ETF product management head has to say about the ETF industry and global outlook.